Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Does the presence of a BRCA 1/2 mutation affect your recommendation for post-mastectomy RT in patients with pT1-2, N0 disease?
Answer from: Radiation Oncologist at Community Practice
It doesn’t influence RT decision.
Sign in or Register to read more
11230
Related Questions
In patients with history of prior axillary surgery, subsequently with breast cancer recurrence, and sentinel lymph nodes mapped to internal mammary area (but were not biopsied), do you offer post-mastectomy radiation to cover the IMNs?
What is your preferred sequencing of adjuvant chemotherapy and PMRT for node + breast cancer?
How would you manage a patient with micrometastatic node positive tumor post mastectomy (no neoadjuvant chemotherapy)?
What are your top takeaways in Breast Cancer from ESMO 2024?
Do young, early-stage breast cancer patients with pCR to chemoimmunotherapy still benefit from PMRT?
Should PMRT be offered for ypN0(i+) disease if only 1-2 nodes were removed in the post-chemotherapy SLNB and there is no plan for a completion AxLND?
How do you choose between ALND and RNI in the setting of LYMPHA or S-Lympha surgery?
Under what circumstances would you pursue completion ALND in a patient with multiple positive sentinel nodes after breast-conserving surgery?
When treating early stage breast cancer with adjuvant RT, what risk factors would lead you to include the level 1 and 2 axilla in patients with pN0(i+) disease?
Do you test /back project various bolus such as mesh or superflab to verify dosimetry and which do you prefer? How do you have staff apply it consistently? eg mesh bolus for chest wall